NimbleGen gains patents covering manufacture, use, and sales of nucleic acid microarrays.



NimbleGen Systems obtained a nonexclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use, and sales of nucleic acid microarrays and related products and services in the research field.

“This licensing agreement with NimbleGen follows from a commercial relationship and enables both companies to better serve customers within the growing microarray market,” says Alan Sherr, vp and chief counsel for licensing at Affymetrix.








This site uses Akismet to reduce spam. Learn how your comment data is processed.